NI-0401 in Active Crohn's Disease

Moderate to Severe Crohn's Disease Clinical Trial

Official title:

A Phase I/IIa, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NI-0401 in Patients With Moderate to Severe Active Crohn´s Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00630643
• Other study ID #: NI-0401-01
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: February 28, 2008
• Last updated: March 6, 2008
• Start date: January 2006
• Est. completion date: December 2007

Study information

• Verified date: February 2008
• Source: NovImmune SA
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium:DGMPUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyPoland: CEBK
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to assess the safety and tolerability of daily intravenous NI-0401 treatment, compared to matching placebo. And to assess the ability of NI-0401 to modulate the CD3 complex on T-cells.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 2007
• Est. primary completion date: December 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Main Inclusion Criteria:

1. Men and women between 18 and 70 years of age.

2. Crohn's Disease Activity Index (CDAI) between 220 and 450.

3. Raised plasma CRP level.

4. Endoscopic inflammation.

5. Crohn's disease of at least 6 months duration, with colitis, ileitis, or ileocolitis, confirmed by endoscopy and histology within 28 days of study day 1.

Main Exclusion criteria

1. Have received or are planned to receive immunization with a live vaccine within 6 weeks prior to receiving study drug and 12 weeks after treatment cessation.

2. Concomitant disease:

• Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, neurological or cerebral disease (including a history of seizure disorders or ongoing chronic active conditions such as chronic active hepatitis)

• Previous diagnosis of, or known, malignancies

• Severe infections, such as hepatitis, pneumonia or pyelonephritis, in the past three months. Less serious infections in the past 3 months, such as acute upper respiratory tract infection (colds) or uncompliant urinary tract infection are permitted at the discretion of the investigator

• Active infection requiring antibiotic therapy

• Serum anti HCV positive, serum HBsAg positive, serum anti-HIV positive

• History of opportunistic infections such as herpes zoster within 2 months prior to screening, evidence of acute CMV or EBV, active Pneumocystic Carinii

• History of active tuberculosis (TB) or currently undergoing treatment for TB. Patients with a positive TB skin test or chest x-ray are ineligible. Patients with a history of bacille Calmette Guerin (BCG) vaccination and a newly positive TB skin test or a chest X-ray showing fibrotic lesions consistent with previous TB are ineligible. The PPD skin test must be read between 48 and 72 hours

• Stool examination positive for enteric pathogens, pathogenic ova or parasites, or Clostridium Difficile toxin within 4 weeks prior to Study Day 1

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Crohn Disease
• Moderate to Severe Crohn's Disease

Intervention

Biological:
• NI-0401 (anti-CD3 mAB)
0.05 mg up to 10 mg

Drug:
• Placebo
Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
NovImmune SA

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of intravenous NI-0401 .		24 weeks	Yes
Secondary	Immunological response defined as the percent change in the modulation of the CD3 complex on T-cells			No